Dyne Launches Phase 3 HARMONIA Trial for DM1 Therapy
March 08, 2026 — Waltham, Massachusetts, USA Clinical-stage biotechnology innovator Dyne Therapeutics has announced the initiation of the Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
March 08, 2026 — Waltham, Massachusetts, USA Clinical-stage biotechnology innovator Dyne Therapeutics has announced the initiation of the Phase...
